Lupus Nephritis from Pathogenesis to New Therapies: An Update
International Journal of Molecular Sciences · 18.08.2024 · 25 (16) · 8981
DOI: 10.3390/ijms25168981 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.08.2024. Verfasst von Annalisa Roveta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research and Innovation Department (DAIRI), "SS Antonio e Biagio e Cesare Arrigo" University Hospital, 15121 Alessandria, Italy. Hauptthemen laut MEDLINE: Lupus Nephritis. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lupus Nephritis (LN) still represents one of the most severe complications of Systemic Lupus Erythematosus (SLE) and a major risk factor for morbidity and mortality. However, over the last few years, several studies have paved the way for a deeper understanding of its pathogenetic mechanisms and more targeted treatments. This review aims to provide a comprehensive update on progress on several key aspects in this setting: pathogenetic mechanisms of LN, including new insight into the role of autoantibodies, complement, vitamin D deficiency, and interaction between infiltrating immune cells and kidney resident ones; the evolving role of renal biopsy and biomarkers, which may integrate information from renal histology; newly approved drugs such as voclosporin (VOC) and belimumab (BEL), allowing a more articulate strategy for induction therapy, and other promising phase III-immunosuppressive (IS) agents in the pipeline. Several adjunctive treatments aimed at reducing cardiovascular risk and progression of chronic renal damage, such as antiproteinuric agents, represent an important complement to IS therapy. Furthermore, non-pharmacological measures concerning general lifestyle and diet should also be adopted when managing LN. Integrating these therapeutic areas requires an effort towards a holistic and multidisciplinary approach. At the same time, the availability of an increasingly wider armamentarium may translate into improvements in patient’s renal outcomes over the next decades.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Innovation Department (DAIRI), "SS Antonio e Biagio e Cesare Arrigo" University Hospital, 15121 Alessandria, Italy.
- Nephrology and Dialysis Unit, "SS Antonio e Biagio e Cesare Arrigo" University Hospital, 15121 Alessandria, Italy.
- Nephrology and Dialysis Unit, IRCCS "San Raffaele" Scientific Institute, 20132 Milan, Italy.
- Department of Internal Medicine, University of Genova, 16126 Genoa, Italy.
- Department of Primary Care, Azienda Socio Sanitaria Territoriale (ASST) of Pavia, 27100 Pavia, Italy.
- Department of Translational Medicine, University of Piemonte Orientale (UPO), 28100 Novara, Italy.
ORCID-Profile: Annalisa Roveta, Emanuele Luigi Parodi, Francesca Tunesi, Guido Merlotti, Alessia Francese, Antonio G Maconi, Marco Quaglia
Zitieren
APA
Roveta, A., Parodi, E. L., Brezzi, B., Tunesi, F., Zanetti, V., Merlotti, G., Francese, A., Maconi, A. G., & Quaglia, M. (2024). Lupus Nephritis from Pathogenesis to New Therapies: An Update. International Journal of Molecular Sciences, 25(16), 8981. https://doi.org/10.3390/ijms25168981
Vancouver
Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. International Journal of Molecular Sciences. 2024;25(16):8981. doi:10.3390/ijms25168981
BibTeX
@article{Roveta2024,
author = {Roveta, Annalisa and Parodi, Emanuele Luigi and Brezzi, Brigida and Tunesi, Francesca and Zanetti, Valentina and Merlotti, Guido and Francese, Alessia and Maconi, Antonio G and Quaglia, Marco},
title = {Lupus Nephritis from Pathogenesis to New Therapies: An Update},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {16},
pages = {8981},
doi = {10.3390/ijms25168981}
}
EUVIMED